Loading
Tempus' blood test for leftover bowel cancer that needs no tumour sample, reported as ctDNA detected or not detected.
Tempus describes xM as a tumour-naive assay for colorectal cancer that gives results from one blood draw to help detect residual disease or recurrence, reported as a binary ctDNA call with a quantitative result. Tempus also sells Personalis' tumour-informed whole-genome test under the name xM (NeXT Personal Dx). The evidence Tempus cites for the tumour-naive test is conference presentations from the GALAXY arm of CIRCULATE-Japan (ASCO 2024) and the VICTORI study (AACR 2025), not a peer-reviewed paper.
A single blood draw is analysed with machine-learning models trained on Tempus' database to tell tumour-derived DNA fragments from normal ones, without first sequencing the tumour.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tempus xM for MRD" OR ABSTRACT:"Tempus xM for MRD" OR TITLE:"tumour-naive" OR ABSTRACT:"tumour-naive" OR TITLE:"Tempus xM" OR ABSTRACT:"Tempus xM") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tempus xM for MRD (tumour-naive), not a curated reading list.
Shares NeXT Personal Dx, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Guardant Reveal, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares NeXT Personal Dx, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Guardant Reveal, NeXT Personal Dx, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment) and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/